Method for preparing stem cell-derived exosome using thermostable and long-acting basic fibroblast growth factor mutant

The use of a stable bFGF variant (TS-bFGF) in stem cell culture media enhances exosome production and therapeutic efficacy, addressing the challenge of low exosome yields and improving anti-inflammatory and regenerative outcomes.

WO2024248216A1PCT designated stage expired Publication Date: 2024-12-05PNP BIOPHARM CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/009242
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2023-06-30
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods are insufficient for producing high yields of stem cell-derived exosomes, which are essential for therapeutic applications due to low exosome production from mammalian cells.

Method used

A method involving the use of a highly stable and long-acting basic fibroblast growth factor variant (TS-bFGF) is developed to promote exosome production from umbilical cord blood stem cells, enhancing exosome yield, anti-inflammatory efficacy, and cell regeneration capabilities.

Benefits of technology

The method significantly increases exosome production and demonstrates superior anti-inflammatory and regenerative effects compared to using natural bFGF, as shown by increased exosome yield, reduced nitric oxide production, and improved wound healing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023009242_05122024_PF_FP_ABST
    Figure KR2023009242_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to: a composition for promoting the production of stem cell-derived exosomes, comprising a thermostable and long-acting bFGF mutant (TS-bFGF); and a method for preparing stem cell-derived exosomes using same. When stem cell-derived exosomes are prepared using the thermostable and long-acting bFGF mutant (TS-bFGF) according to the present invention, the production of the exosomes is promoted, and the obtained exosomes exhibit a high anti-inflammatory effect and cell regeneration and wound regeneration effects.
Need to check novelty before this filing date? Find Prior Art

Description

Method for producing stem cell-derived exosomes using a highly stable, active, and sustained-release basic fibroblast growth factor variant

[0001] The present invention relates to a composition for promoting the production of stem cell-derived exosomes and a method for producing stem cell-derived exosomes using the same, and more particularly, to a composition for promoting the production of stem cell-derived exosomes containing a highly stable, active, sustained-release bFGF variant (TS-bFGF) and a method for producing stem cell-derived exosomes using the same.

[0002]

[0003] Mesenchymal stem cells (MSCs) are multipotent stem cells derived from tissues such as umbilical cord, bone marrow, adipose tissue, and the placenta, and can differentiate into numerous cell types. Among these, umbilical cord-derived mesenchymal stem cells (UCMSCs) are known to be younger, have superior cell regeneration capabilities, and have less immunogenicity than bone marrow or adipose-derived MSCs. Therefore, they are used as parent stem cells for producing exosomes for therapeutic purposes, as well as in stem cell therapies.

[0004] Exosomes (or extracellular vesicles or EVs) are nano-sized (approximately 30–150 nm) extracellular vesicles that are known to play an important role in intercellular signaling, inflammatory responses, homeostasis, and intercellular transport of essential molecules such as inflammation-related molecules, cytokines, and microRNAs (miRNAs). Clinical trials using exosomes have shown that, unlike parent stem cells, exosomes do not exhibit immunogenicity or tumorigenicity. Despite this great potential as a therapeutic agent, most mammalian cells do not release sufficient exosomes for therapeutic purposes, which has been pointed out as one of the important challenges to be solved in the development of exosome-based therapeutics.

[0005] Commercial use of these exosomes requires large quantities of high-quality exosomes. However, the current amount of exosomes available from stem cells is very small, and the development of substances that can increase the production of stem cell-derived exosomes remains inadequate. Consequently, the need for novel methods and substances that promote the production of stem cell-derived exosomes has arisen.

[0006] Accordingly, the present inventors have made great efforts to develop a method for producing exosomes from umbilical cord blood stem cells (UCMSCs) at a high yield, and as a result, have developed a highly stable, long-acting, active bFGF mutant (TS-bFGF) (Korean Patent Application No. 10-2023-0069536) with thermostability and long-term action, and when umbilical cord blood stem cells (UCMSCs) are cultured using this, exosomes can be produced at a high yield, and it has been confirmed that the exosomes produced in this way have superior anti-inflammatory efficacy and cell and tissue regeneration efficacy compared to the case where natural bFGF (WT-bFGF) is used, and thus the present invention has been completed.

[0007]

[0008] Summary of the invention

[0009] The purpose of the present invention is to provide a composition for promoting the production of stem cell-derived exosomes for producing stem cell-derived exosomes with high yield.

[0010] The purpose of the present invention is to provide a method for producing stem cell-derived exosomes with high yield.

[0011] To achieve the above purpose, the present invention provides a composition for promoting the production of stem cell-derived exosomes, comprising a high-stability, sustained-activity bFGF variant (TS-bFGF) represented by the amino acid sequence of SEQ ID NO: 1.

[0012] The present invention provides a method for producing stem cell-derived exosomes comprising the following steps:

[0013] (a) a step of culturing stem cells in a stem cell culture medium containing a highly stable, active, sustained-release bFGF variant (TS-bFGF) represented by the amino acid sequence of sequence number 1; and

[0014] (b) A step of isolating and obtaining exosomes from the culture solution of the above stem cells.

[0015] The present invention also provides an anti-inflammatory composition containing exosomes produced by the above method.

[0016] The present invention also provides a composition for cell or tissue regeneration containing exosomes produced by the above method.

[0017]

[0018] Figure 1 is a graph showing the results of comparing the yield of exosomes obtained by culturing umbilical cord-derived mesenchymal stem cells (UCMSCs) in 2D (two-dimensional culture) and 3D (three-dimensional culture or spheroid culture) with treatment of native bFGF (WT-bFGF) and a highly stable, sustained-activity bFGF variant (TS-bFGF).

[0019] Figure 2 is a graph showing the results of comparing the anti-inflammation efficacy of exosomes obtained by culturing UCMSCs in 2D and 3D and treating them with native bFGF (WT-bFGF) and a highly stable, long-acting bFGF mutant (TS-bFGF), as measured by measuring the amount of nitric oxide (NO).

[0020] Figure 3 is a graph showing the results of comparing the cellular regeneration efficacy of exosomes obtained by culturing UCMSCs in 2D and 3D with treatment of native bFGF (WT-bFGF) and a highly stable, active, sustained-release bFGF mutant (TS-bFGF), as measured by cell viability (%).

[0021] Figure 4 is a photograph showing the results of comparing the wound healing efficacy of exosomes obtained by culturing UCMSCs in 2D and 3D and treating them with native bFGF (WT-bFGF) and a highly stable, active, and sustained-release bFGF mutant (TS-bFGF) over time through the wound area.

[0022]

[0023] Detailed description of the invention and preferred embodiments

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Generally, the nomenclature used herein is well known and commonly used in the art.

[0025]

[0026] In the present invention, it was confirmed that when stem cells are cultured using a bFGF variant (TS-bFGF) having thermostability and long-term action, exosome production of stem cells is promoted, and the produced exosomes have excellent anti-inflammatory and regenerative effects.

[0027] Accordingly, the present invention relates to a composition for promoting the production of stem cell-derived exosomes comprising a highly stable, active, sustained-release bFGF variant (TS-bFGF) represented by the amino acid sequence of SEQ ID NO: 1.

[0028] The high-stability, long-acting bFGF variant (TS-bFGF) used in the present invention has an amino acid sequence of sequence number 1 and is encoded by a base sequence of sequence number 2.

[0029]

[0030] In the present invention, the stem cells may be characterized by being selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells, and it is preferable to use mesenchymal stem cells derived from umbilical cord blood.

[0031] In this specification, "embryonic stem cell" refers to a cell extracted during the developmental process of an embryo, and means an inner cell mass extracted from a blastocyst embryo just before the fertilized egg is implanted in the mother's uterus and cultured in vitro.

[0032] In this specification, “induced pluripotent stem cell (iPSC)” refers to cells that are induced to have pluripotent differentiation ability through an artificial dedifferentiation process from differentiated cells, and can be used with the same meaning as “induced pluripotent stem cell.”

[0033] Popular artificial reprogramming processes can be performed by introducing viral-mediated or non-viral vectors using retroviruses, lentiviruses and Sendaiviruses, non-viral-mediated reprogramming factors using proteins and cell extracts, etc., or by introducing reprogramming processes using stem cell extracts, compounds, etc.

[0034] The above-mentioned induced pluripotent stem cells have almost the same characteristics as embryonic stem cells, specifically, they have a similar cell shape, similar gene and protein expression, have pluripotency in vitro and in vivo, form teratoma, and when inserted into a mouse blastocyst, form chimera mice and enable germline transmission of genes.

[0035] The term "promotion of production" in this specification means that the production, creation, release, etc. of a specific substance increases within the same period of time compared to a control group.

[0036] Specifically, it means that the quantity of exosomes produced from stem cells and the content of proteins, RNA, etc. in exosomes increase.

[0037] When the composition of the present invention is a medium composition, the "medium composition" means a composition containing essential components necessary for the growth, survival and proliferation of cells in vitro, and includes all stem cell culture media commonly used in the field, for example, DMEM (Dulbecco's Modified Eagle's Medium), DMEM-high glucose (Dulbecco's Modified Eagle's Medium high glucose), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI 1640, DMEM / F-10 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-10), DMEM / F-12 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12), α-MEM (α-Minimal essential Medium), G-MEM (Glasgow's Minimal Essential Medium), IMDM (Isocove's Modified Dulbecco's Medium), Commercially manufactured media such as KnockOut DMEM, E8 (Essential 8 Medium), or artificially synthesized media can be used, but are not limited thereto.

[0038] In the present invention, the high-stability, sustained-activity bFGF variant (TS-bFGF) is preferably added at a concentration of 1 to 100 ng / mL, and more preferably, it is preferably added at a concentration of 5 to 30 ng / mL.

[0039] The composition according to the present invention may further include a known exosome production promoting substance in addition to the above-described components.

[0040] As used herein, "exosomes" are cell-derived vesicles that exist in the body fluids of nearly all eukaryotic organisms. Exosomes are approximately 30-150 nm in diameter, which is larger than LDL proteins but much smaller than red blood cells.

[0041] These exosomes can be released from cells when multivesicular bodies fuse with the cell membrane, or they can be released directly from the cell membrane. It is well known that these exosomes perform important and specialized functions, such as coagulation and intercellular signaling.

[0042] From another aspect, the present invention relates to a method for producing stem cell-derived exosomes, comprising the following steps:

[0043] (a) a step of culturing stem cells in a stem cell culture medium containing a highly stable, active, sustained-release bFGF variant (TS-bFGF) represented by the amino acid sequence of sequence number 1; and

[0044] (b) A step of isolating and obtaining exosomes from the culture solution of the above stem cells.

[0045] According to an embodiment of the present invention, the culture medium in which UCMSCs were cultured was collected and centrifuged at 300 g for 10 minutes to remove remaining cells and cell debris. The supernatant was taken and filtered using a 0.22 μm filter, and then centrifuged at 10,000 g at 4 ° C for 30 minutes using a high speed centrifuge. The centrifuged supernatant was collected again and centrifuged at 187,000 g at 4 ° C for 120 minutes using an ultracentrifuge to remove the supernatant. The exosomes remaining in the lower layer were diluted in PBS (phosphate buffered saline) and used in the following examples.

[0046] In the present invention, the stem cells may be characterized by being selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells, and it is preferable to use mesenchymal stem cells derived from umbilical cord blood.

[0047] In the present invention, the high-stability, sustained-activity bFGF variant (TS-bFGF) is preferably added at a concentration of 1 to 50 ng / mL, and more preferably, it is preferably added at a concentration of 5 to 30 ng / mL.

[0048] From another perspective, the present invention relates to an anti-inflammatory composition containing exosomes produced by the above method.

[0049] In one embodiment of the present invention, the anti-inflammatory effect of UCMSC-derived exosomes was confirmed using macrophages (Raw264.7 cells), and it was confirmed that nitric oxide production was reduced in the group treated with exosomes obtained by treating a highly stable, active, sustained-release bFGF mutant (TS-bFGF) compared to the group treated with exosomes obtained by treating a native type (WT-bFGF) (Fig. 2).

[0050] In another aspect, the present invention relates to a composition for cell or tissue regeneration containing exosomes produced by the above method.

[0051] In one embodiment of the present invention, the wound regeneration efficacy of UCMSC-derived exosomes was confirmed through a scratch test using human dermal fibroblasts (NHDF), and it was confirmed that the group treated with exosomes obtained by treating with a highly stable, long-acting bFGF mutant (TS-bFGF) exhibited significantly higher wound regeneration ability than the group treated with exosomes obtained by treating with native bFGF (WT-bFGF) (Fig. 4).

[0052]

[0053] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.

[0054]

[0055] Example 1: Production of TS-bFGF protein

[0056] After cloning the high-stability, sustained-activity bFGF mutant (TS-bFGF) gene (SEQ ID NO: 2) into an Escherichia coli expression vector, the constructed pPnP TS-bFGF expression vector DNA (Korean Patent Application No. 10-2023-0069536) was expressed in BL21 codon+(DE3) cells (Novagen). Soluble TS-bFGF was applied to a His-Trap FF column homogenized with a 100 mM Tris, 150 mM NaCl buffer solution (pH 8.0), and the TS-bFGF that flowed out without binding to the column was collected and further purified by heparin-Sepharose column chromatography. The purified TS-bFGF was oxidized by treating with different amounts of cysteine ​​and cystine under basic pH conditions, and then ultrafiltration was performed for solution exchange and concentration. Purified TS-bFGF was stored at -20°C in lyophilized powder form.

[0057]

[0058] Example 2: Isolation of stem cell-derived exosomes by TS-bFGF treatment

[0059] Umbilical cord blood-derived stem cells (UCMSCs) (CEFO Bio) were cultured in 2D and 3D cultures (spheroid cultures) for 3 days in 100 mm petri dishes using MEM-α (Gibco) containing 10 ng / mL WT-bFGF (Peprotech) or 10 ng / mL TS-bFGF (Example 1) and 10% exosome-free FBS.

[0060] For exosome isolation, the culture medium in which UCMSCs were cultured was collected and centrifuged at 300 g for 10 minutes to remove remaining cells and cell debris. The supernatant was collected, filtered using a 0.22 μm filter, and centrifuged at 10,000 g at 4 °C for 30 minutes using a high-speed centrifuge. The centrifuged supernatant was collected again and centrifuged at 187,000 g at 4 °C for 120 minutes using an ultracentrifuge to remove the supernatant. The exosomes remaining in the lower layer were diluted in PBS (phosphate-buffered saline) and used in the following examples.

[0061] As a result of confirming the production yield of the obtained exosomes, as shown in Fig. 1, in 3D culture, it was confirmed that the exosome yield was significantly superior when TS-bFGF was treated (5980 EV / cell) than when WT-bFGF was treated (4600 EV / cell).

[0062]

[0063] Example 3: Confirmation of the anti-inflammatory efficacy of exosomes derived from UCMSCs cultured with TS-bFGF.

[0064] The anti-inflammatory efficacy of the UCMSC-derived exosomes obtained in Example 2 was confirmed using macrophages (Raw264.7 cells).

[0065] Raw264.7 cells (ATCC) were seeded at 1.5E+5 cells / well (24 wells) using DMEM high-glucose (Gibco) medium containing 10% FBS. After 12 h of culture, 1 x 10 cells were seeded and cultured using DMEM high-glucose medium containing 10% exosome-depleted FBS, and medium containing LPS (10 ng / mL), an inflammatory substance. 9After 24 hours of culture with dog exosomes or dexamethasone (10 μM) as a positive control, the anti-inflammation efficacy was measured by measuring the amount of nitric oxide (NO) in the culture medium.

[0066] The amount of nitric oxide produced was analyzed by the Griess assay using Griess reagent.

[0067] As a result, as shown in Fig. 2, it was confirmed that nitric oxide production was reduced in the group treated with exosomes obtained by treating TS-bFGF compared to the group treated with exosomes obtained by treating WT-bFGF.

[0068]

[0069] Example 4: Confirmation of the regenerative efficacy of exosomes derived from UCMSCs cultured with TS-bFGF.

[0070] The regenerative efficacy of the UCMSC-derived exosomes obtained in Example 2 was confirmed using human dermal fibroblasts (NHDF p11).

[0071] NHDF p11 cells (PromoCell) were seeded at 5E+3 cells / well (96 wells) using DMEM high-glucose (Gibco) medium containing 10% exosome-depleted FBS, and 1 x 10 7 After culturing for 24 hours with the addition of 1 x 109 exosomes, cell regeneration ability was confirmed through MTT assay.

[0072] As a result, as shown in Fig. 3, it was confirmed that the group treated with exosomes obtained by treating TS-bFGF showed significantly higher cell viability (cell viability %) than the group treated with exosomes obtained by treating WT-bFGF.

[0073]

[0074] Example 5: Confirmation of the wound regeneration efficacy of exosomes derived from UCMSCs cultured with TS-bFGF.

[0075] The wound regeneration efficacy of the UCMSC-derived exosomes obtained in Example 2 was confirmed using human dermal fibroblasts (NHDF).

[0076] NHDF cells (PromoCell) were seeded at 1E+4 cells / well (6 wells) using DMEM high-glucose (Gibco) medium containing 10% FBS and cultured to confluency. After culture to confluency, cell proliferation was inhibited by treating with 10 ug / ml mitomycin C for 2 hours. After scratching the cells, 1 x 107 or 1 x 10 9 After adding dog exosomes and further culturing for 0 to 24 hours, the degree of wound healing was confirmed by comparing the wound area.

[0077] As a result, as shown in Fig. 4, it was confirmed that the group treated with exosomes obtained by treating TS-bFGF exhibited significantly higher wound regeneration ability than the group treated with exosomes obtained by treating WT-bFGF.

[0078]

[0079] When stem cell-derived exosomes are produced using the high-stability, sustained-activity bFGF variant (TS-bFGF) according to the present invention, exosome production is promoted, and the obtained exosomes exhibit high anti-inflammatory effects and cell regeneration and wound regeneration effects.

[0080]

[0081] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

[0082]

[0083] Electronic file attached.

Claims

1. A composition for promoting the production of stem cell-derived exosomes, comprising a highly stable, active, sustained-release bFGF variant (TS-bFGF) represented by the amino acid sequence of sequence number 1.

2. A composition according to claim 1, characterized in that the stem cells are selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells.

3. A composition according to claim 1, characterized in that the mesenchymal stem cells are mesenchymal stem cells derived from umbilical cord blood.

4. A composition characterized in that the high-stability, sustained-activity bFGF variant (TS-bFGF) in the first paragraph is added at a concentration of 1 to 100 ng / mL.

5. A composition characterized in that in the fourth paragraph, the high-stability, sustained-activity bFGF variant (TS-bFGF) is added at a concentration of 5 to 30 ng / mL.

6. A method for producing stem cell-derived exosomes comprising the following steps: (a) a step of culturing stem cells in a stem cell culture medium containing a high-stability, long-acting bFGF variant (TS-bFGF) represented by the amino acid sequence of sequence number 1; and (b) A step of isolating and obtaining exosomes from the culture solution of the above stem cells.

7. A method according to claim 6, characterized in that the stem cells are selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells.

8. A method according to claim 6, characterized in that the mesenchymal stem cells are mesenchymal stem cells derived from umbilical cord blood.

9. A method according to claim 6, characterized in that the high-stability, sustained-activity bFGF variant (TS-bFGF) is included at a concentration of 1 to 100 ng / mL.

10. An anti-inflammatory composition containing exosomes produced by the method of Article 9.

11. A composition for cell or tissue regeneration containing exosomes produced by the method of Article 6.

Citation Information

Patent Citations

  • A human basic fibroblast factor-2 mutant with high stability and use of the same

    KR1020160118784A

  • Thermostable FGF2 polypeptide, use thereof

    KR1020180080335A

  • A Power-efficient Soft Pneumatic Actuator Using Magnet Chamber Structure

    KR102561982B1

  • Thermostable variants of fibroblast growth factors

    US20120225479A1

  • FGF-2 having enhanced stability

    US20130236959A1